Patents Assigned to KALLYOPE, INC.
  • NK3 modulators and uses thereof
    Patent number: 12281114
    Abstract: The present disclosure relates to compounds useful as modulators of neurokinin receptor 3 (NK3) for the treatment of conditions or disorders.
    Type: Grant
    Filed: August 12, 2024
    Date of Patent: April 22, 2025
    Assignee: KALLYOPE, INC.
    Inventors: Shuwen He, Scott B. Joseph, Christopher Moyes, Tesfaye Biftu, Santhosh F. Neelamkavil
  • GPR40 agonists
    Patent number: 12264171
    Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: April 1, 2025
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He
  • AMPK activators
    Patent number: 11851429
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 26, 2023
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He, Ann Weber, Nancy Thornberry, Lisa Krug, Paul Richards, Brett Lauring
  • GPR119 agonists
    Patent number: 11512065
    Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: November 29, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He, Christopher Moyes
  • AMPK activators
    Patent number: 11407768
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: August 9, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He
  • AMPK activators
    Patent number: 11279702
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: March 22, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He